KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Receivables: 2017-2024

Historic Receivables for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Dec 2024 value amounting to $1.3 billion.

  • Amneal Pharmaceuticals' Receivables rose 20.27% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 billion, marking a year-over-year increase of 12.17%. This contributed to the annual value of $1.3 billion for FY2024, which is 8.51% up from last year.
  • As of FY2024, Amneal Pharmaceuticals' Receivables stood at $1.3 billion, which was up 8.51% from $1.2 billion recorded in FY2023.
  • Amneal Pharmaceuticals' 5-year Receivables high stood at $1.4 billion for FY2022, and its period low was $1.2 billion during FY2021.
  • Its 3-year average for Receivables is $1.3 billion, with a median of $1.3 billion in 2024.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Receivables climbed by 14.69% in 2022, and later decreased by 12.20% in 2023.
  • Yearly analysis of 5 years shows Amneal Pharmaceuticals' Receivables stood at $1.3 billion in 2020, then fell by 8.20% to $1.2 billion in 2021, then increased by 14.69% to $1.4 billion in 2022, then dropped by 12.20% to $1.2 billion in 2023, then grew by 8.51% to $1.3 billion in 2024.